Recent analysis of archived temporal arteries (TAs) acquired from 13 pathology laboratories in the US, Canada, Iceland, France, Germany and Israel from patients with pathologically-verified giant cell arteritis (GCA-positive) and TAs from patients with clinical features and laboratory abnormalities of GCA but whose TAs were pathologically negative (GCA-negative) revealed VZV antigen in most TAs from both groups. Despite formalin-fixation, VZV DNA was also found in many VZV-antigen positive sections that were scraped, subjected to DNA extraction, and examined by PCR with VZV-specific primers. Importantly, in past studies, the pathological diagnosis (GCA-positive or -negative) was known to the neurovirology laboratory. Herein, GCA-positive and GCA-negative TAs were provided by an outside institution and examined by 4 investigators blinded to the pathological diagnoses. VZV antigen was found in 3/3 GCA-positive TAs and in 4/6 GCA-negative TAs, and VZV DNA in 1/3 VZV antigen-positive, GCA-positive TAs and in 3/4 VZV antigen-positive, GCA-negative TAs. VZV DNA was also detected in one GCA-negative, VZV-antigen negative TA. Overall, the detection of VZV antigen in 78% of GCA-positive and GCA-negative TAs is consistent with previous reports on the prevalence of VZV antigen in patients with clinically suspect GCA.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4834150PMC
http://dx.doi.org/10.1016/j.jns.2016.03.020DOI Listing

Publication Analysis

Top Keywords

vzv antigen
16
gca-negative tas
16
gca-positive gca-negative
12
gca-positive tas
12
vzv dna
12
tas
10
vzv
9
giant cell
8
cell arteritis
8
arteritis gca-positive
8

Similar Publications

A VZV-gE subunit vaccine decorated with mPLA elicits protective cellular immmune responses against varicella-zoster virus.

Int Immunopharmacol

January 2025

Department of Pharmaceutics, School of Pharmacy, Ningxia Medical University, Yinchuan, Ningxia, China. Electronic address:

Herpes zoster is an acute infectious skin disease caused by the reactivation of latent varicella-zoster virus, vaccination, such as subunit vaccine with good safety, can effectively prevent shingles through increasing immunity of the body. However, protein antigens are prone to degradation and inactivation, which alone is generally not sufficient to induce potent immune effect. In this study, the liposomal vaccine platform modified with mPLA (TLR4 agonist) was developed to improve the immunogenicity of glycoprotein E (VZV-gE) derived from herpes zoster virus.

View Article and Find Full Text PDF

Background: Varicella can lead to severe complications in immunocompromised children, including those undergoing hematopoietic stem cell transplantation (HSCT) or chemotherapy. Preventing primary varicella zoster virus (VZV) infection is crucial in these populations to mitigate morbidity and mortality. This study aimed to evaluate the immunogenicity and safety of the live attenuated MAV/06 varicella vaccine in pediatric patients post-HSCT and post-chemotherapy.

View Article and Find Full Text PDF

Herpes zoster (HZ) is increasingly common in the aging and is experienced by approximately one in three people in their lifetime. It is also relatively common in immune-compromised people. Acute HZ causes severe pain, reduced quality of life and severe complications, including prolonged pain, or postherpetic neuralgia (PHN), and ocular zoster, which may rarely progress to blindness.

View Article and Find Full Text PDF

VZV IE4 downregulates cellular surface MHC-I via sequestering it to the Golgi complex.

Cell Mol Life Sci

December 2024

Department of Microbiology, Immunology and Infectious Diseases, University of Calgary, Calgary, AB, Canada.

Article Synopsis
  • Varicella-zoster virus (VZV) infection reduces surface expression of MHC-I by retaining it in the Golgi complex, but the mechanism behind this is not fully clear.
  • The study identifies the VZV IE4 protein as a key factor that interacts with the human leukocyte antigen C (HLA-C), leading to its co-localization in the Golgi and downregulation of MHC-I on the cell surface.
  • A mutated version of IE4 (mIE4) restores MHC-I surface expression, indicating that VZV IE4 plays a role in evading host immune responses by disrupting the MHC-I presentation pathway.
View Article and Find Full Text PDF

Broad Analysis of Serum and Intrathecal Antimicrobial Antibodies in Multiple Sclerosis Underscores Unique Role of Epstein-Barr Virus.

Neurol Neuroimmunol Neuroinflamm

January 2025

From the Department of Neurology (F.P., C.O., P.S., M.N., K.R.), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin; Institute for Experimental Immunology (D.W., T.L., K.S., E.G.-G.), affiliated with EUROIMMUN Medizinische Labordiagnostika AG, Luebeck; and Molecular Neuroimmunology Group (B.W., S.J.), Department of Neurology, University of Heidelberg, Germany.

Article Synopsis
  • - The study investigates the relationship between the Epstein-Barr virus (EBV) and multiple sclerosis (MS) by analyzing the presence of antibodies against EBV and other common microbes in patients with MS, revealing a universal EBV seroprevalence among participants.
  • - A total of 50 MS patients were tested for antibodies in their cerebrospinal fluid (CSF) and serum, finding that while all patients were EBV positive, the production of specific antibodies in the CSF was significantly lower for EBV compared to other viruses like measles and VZV.
  • - The results indicate that even though almost all MS patients have been exposed to EBV, the actual production of antibodies against EBV in the central
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!